Landiolol, a new ultra-short-acting beta1-blocker, reduces anaesthetic requirement during sevoflurane/N(2)O/fentanyl anaesthesia in surgical patients.

BACKGROUND AND OBJECTIVE: It is known that esmolol, a short-acting beta1-blocker, reduces anaesthetic requirement. In this study, we evaluated whether a low dose of landiolol, a new ultra-short-acting beta1-blocker, can reduce the sevoflurane requirement. METHODS: Twenty-five patients undergoing hip surgery were randomly divided into two groups. Group A (n = 13) received landiolol (bolus injection of 0.031 mg.kg(-1) and continuous infusion at a rate of 0.01 mg.kg(-1).min(-1)). Group B (n = 12) received physiological saline. Landiolol and physiological saline were started before the induction of anaesthesia and continued until the end of anaesthesia. Anaesthesia was maintained with sevoflurane, 60% N(2)O and fentanyl. Sevoflurane concentration was controlled to keep the bispectral index at approximately 50. The end-tidal sevoflurane concentration and haemodynamics were measured during anaesthesia. RESULTS: The average end-tidal sevoflurane concentration in group A was significantly lower than that in group B (1.2 +/- 0.30 vs. 1.8 +/- 0.3%, P < 0.01). Maximum values of systolic arterial pressure showed no difference between the groups, whereas the maximum value of heart rate in group A was significantly less than that in group B (61 +/- 10 vs. 76 +/- 14 beats min(-1), P < 0.05). CONCLUSION: The results suggest that a low dose of landiolol significantly reduces the intraoperative sevoflurane requirement during sevoflurane/N(2)O/fentanyl anaesthesia in patients undergoing hip surgery.

[Case of fulminant type 1 diabetes mellitus complicated with acute renal failure treated with continuous hemodiafiltration].

A 50-year-old male patient developed diabetic ketoacidosis with shock, acute renal failure treated with continuous hemodiafiltration (CHDF) and high serum CPK levels. Because of acute onset of ketoacidosis accompanied with an elevation of serum amylase, and negative findings of antibodies associated with autoimmune type 1 diabetes mellitus, he was diagnosed as a fulminant type 1 diabetes mellitus, which is a newly established subtype of type 1 diabetes mellitus. We managed to keep blood glucose concentrations within 150-200 mg x dl(-1) with continuous insulin intravenous infusion, and controlled circulation with dopamine. Since the blood glucose on admission was extremely high (1,870 mg x dl(-1)), the severe dehydration due to extreme hyperglycemia might have caused acute renal failure (ARF) and rhabdomyolysis. He was treated with CHDF for them. In a case of fulminant type 1 diabetes mellitus complicated with ARF early intensive support including CHDF for ARF must be considered in addition to intensive insulin therapy.

[The clinical course of microalbumiuria in 4 burn patients].

BACKGROUND: In burn patients, microvascular permeability is increased. It is difficult to decide the time to administer albumin because it may induce pulmonary edema in the re-filling period. One report shows that microalbuminuria is correlated with endothelial injury and systemic microvascular permeability. METHODS: We measured urinary albumin/creatinine ratio (ACR) in 4 burn patients for 48 hours after injury. RESULTS: In all patients, ACR was elevated in the early period after injury. Moreover, ACR in 2 severe burn patients with burn total body area of over 30% was above the normal range. CONCLUSIONS: The present results show that ACR seems to be correlated with the level of microvascular permeability in 4 burn patients. We conclude that ACR may be a useful indicator to decide the time to administer albumin to a burn patient. However, further investigation is required to decide the threshold value of ACR in a severe burn patient whose ACR are kept above the normal range in the long-term.

Preoperative administration of intravenous flurbiprofen axetil reduces postoperative pain for spinal fusion surgery.

PURPOSE: The aim of the study was to investigate postoperative analgesia and the opioid-sparing effect of the preoperative administration of intravenous flurbiprofen axetil in patients undergoing spinal fusion surgery. METHODS: Thirty-six patients were randomly allocated into one of three groups. Group A received preoperative flurbiprofen axetil, 1 mg x kg(-1). Group B received postoperative flurbiprofen axetil, 1 mg x kg(-1). Group C received a placebo. All groups were given a standardized anesthesia and intravenous morphine via a patient-controlled analgesia device for postoperative analgesia. The pain score was evaluated by a visual analog scale (VAS) at 0 (T(0)), 1 (T(1)), 2 (T(2)), 6 (T(3)), 12 (T(4)), and 24 (T(5)) h after surgery, and the morphine requirement was recorded during the study period. RESULTS: VAS in group A was significantly lower than that in group B at T(0) and T(1). VAS in group A was significantly lower than that in group C throughout the time course after surgery. Postoperative morphine consumption in group A was significantly lower than that in groups B and C at T(0) to T(3). CONCLUSION: As compared with postoperative administration, preoperative administration of intravenous flurbiprofen axetil provides better postoperative analgesia and an opioid-sparing effect in patients undergoing spinal fusion surgery under general anesthesia.